Florian Brand - Psychedelics Market | ATAI Funding Model | Compound Therapeutics

On this episode of the SPEED CHANGE REPEAT Podcast we are talking with Florian Brand who is CEO and Co-Founder at ATAI Life Sciences. 

The company is aiming to develop differentiated treatments for patients suffering from mental health orders.

Having collected over $500m in capital with noteable backing from investors such as Cathie Wood at ARK Invest, ATAI is at the forefront when it comes to the psychedelics market. 

Together with Florian we are covering the early founding of the company and dive deep into the company's funding model for compound development as well as the role of digital therapeutics in ATAI's treatment strategy.